ClinicalTrials.gg
DrugBiological

Sugemalimab clinical trials

Also written CS1001.

studies test it
17
open now
6
in phase 3
6
first study started
2017

How each study uses sugemalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the sugemalimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
24 Jul 2024 · Cejemly · EMEA/H/C/006088 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

CS1001 monoclonal antibody
3
Sugemalimab
3
Sugemalimab and Chemotherapy
2

Development codes

CS1001
7

Studies by the year they started

16 studies that test it; most in 2018 (5); 1 more planned to start later

Studies that test sugemalimab, by start year
YearStudies
20171
20185
20193
20201
20211
20233
20241
20251

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
7
Phase 3
6
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 5

CStone Pharmaceuticals (11) · Sichuan University (1) · Peking Union Medical College (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Sun Yat-sen University (1) · Hunan Cancer Hospital (1) · Suzhou Zelgen Biopharmaceuticals Co.,Ltd (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Sugemalimab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 2

Studies that test sugemalimab.

Studies

Open first, then newest update. How each study uses sugemalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 1 — sugemalimab is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with sugemalimab

Codes

What other systems call sugemalimab · ClinicalTrials.gg INT001923

  • MeSH (NLM) C000723018sugemalimabOne source ClinicalTrials.gov
  • UNII (FDA) 90IQR2I6TRSUGEMALIMABOne source FDA
  • NCI Thesaurus C154550SugemalimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.